Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial
NCT05361811 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 70
Last updated 2026-02-19
Summary
Background:
RASopathies are a group of genetic diseases that affect a child s development. They cause physical, cognitive, and behavioral symptoms. Caring for a child with a RASopathy can be stressful. Acceptance and Commitment Therapy (ACT) is a therapy that helps people become more aware and accepting of difficult thoughts and feelings. ACT has been found to be helpful for parents with high parenting stress.
Objective:
To find out if Acceptance and Commitment Therapy (ACT) can help caregivers of children with a RASopathy better cope with parenting stress.
Eligibility:
People aged 18 years or older who care for a child (younger than 18 years) with a RASopathy. The child must live with the caregiver at least 50% of the time.
Design:
The study is fully remote. Participants need a mobile device that can play audio and video and connect to the internet. They can borrow an iPod if needed.
Participants will download a free app called MetricWire. They will use this app to watch videos and answer questions.
The first 8 participants will be in a pilot study. They will receive the ACT intervention starting the first week after they begin the study.
After the pilot study, we will start a new phase called the randomized trial. In this phase, participants will have a 50-50 chance of being in the group that will start the intervention right away or the group that will start the intervention after about 2 months.
Participants will fill out surveys on 5 random days each week. These surveys have 7 questions and take about 2 minutes. They will also fill out 3 longer questionnaires: once before ACT begins, once just after the 8-week study period, and once about 3 months later. Questions will cover topics including:
Parenting stress
Life satisfaction
Self-compassion
Uncomfortable feelings and thoughts
Mindfulness
Participants will take part in an 8-week ACT intervention. They will have one 75-minute session with an ACT coach in the first week.
Participants will watch 9- to 17-minute videos each week. The videos talk about how to practice ACT techniques to cope with parenting stress.
Participants will have 20- to 30-minute coaching sessions in weeks 3 and 6. The coach will help them practice exercises and work through any problems.
Conditions
- Neurofibromatosis 1
- Noonan Syndrome
- Legius Syndrome
- Cardiofaciocutaneous Syndrome
- Costello Syndrome
Interventions
- BEHAVIORAL
-
Waitlist
8 weeks of maintaining usual routine followed by 8-week intervention that emphasizes mindfulness, acceptance, perspective taking, and values-based actions.
- BEHAVIORAL
-
ACT Intervention
8-week intervention that emphasizes mindfulness, acceptance, perspective taking, and values-based actions.
Sponsors & Collaborators
-
National Cancer Institute (NCI)
lead NIH
Principal Investigators
-
Staci M Peron, Ph.D. · National Cancer Institute (NCI)
Study Design
- Allocation
- RANDOMIZED
- Purpose
- SUPPORTIVE_CARE
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2024-01-10
- Primary Completion
- 2027-06-01
- Completion
- 2027-12-31
Countries
- United States
Study Locations
More Related Trials
-
Safety and Efficacy of AFQ056 in Adult Patients With Fragile X Syndrome
NCT01253629 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of TAK-625 for the Treatment of Alagille Syndrome (ALGS)
NCT05543174 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas
NCT00634270 ·Status: COMPLETED ·Phase: PHASE2
-
Studies in Patients With Tuberous Sclerosis Complex
NCT03276195 ·Status: COMPLETED
-
Repurposing 5-Azacytidine for the Treatment of Muscle Contractures in Children With Cerebral Palsy
NCT06377085 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE1
-
Comprehensive Assessment of Reactions to Pharmacogenetics in Complex Care Patients
NCT07060300 ·Status: ENROLLING_BY_INVITATION ·Phase: NA
-
Miglustat in Niemann-Pick Type C Disease
NCT00517153 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Benefit, Safety, PK and PD Study of AT-007 in Pediatric Subjects With Classic Galactosemia
NCT04902781 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Multicenter Extension Study of Taliglucerase Alfa in Adult Subjects With Gaucher Disease
NCT01422187 ·Status: COMPLETED ·Phase: PHASE3
-
Long-term, Safety and Tolerability Study of AFQ056 in Adolescent Patients With Fragile X Syndrome (Open-label)
NCT01433354 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Faslodex in McCune-Albright Syndrome
NCT00278915 ·Status: COMPLETED ·Phase: PHASE2
-
The Brain and Neuropsychological Functioning in Adults With Sapropterin Dihydrochloride Treated Phenylketonuria
NCT02297347 ·Status: COMPLETED
-
Inhibition of Reverse Transcription in Aicardi-Goutières Syndrome
NCT04731103 ·Status: COMPLETED ·Phase: PHASE2
-
DFT383 in Pediatric Participants With Nephropathic Cystinosis
NCT06910813 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Combining Lovastatin and a Parent-Implemented Language Intervention for Fragile X Syndrome
NCT02642653 ·Status: COMPLETED ·Phase: PHASE4
-
Dose Finding Trial of MK-7075 in Children and Adults With Proteus Syndrome
NCT02594215 ·Status: COMPLETED ·Phase: PHASE1
-
A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCD
NCT02451696 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)
NCT05371613 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
A Study to Assess Efficacy and Safety of RT001 in Subjects With Infantile Neuroaxonal Dystrophy
NCT03570931 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3
-
Stopping TSC Onset and Progression 2: Epilepsy Prevention in TSC Infants
NCT04595513 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Gene Therapy for Fanconi Anemia, Complementation Group A
NCT04248439 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas
NCT06961565 ·Status: RECRUITING ·Phase: PHASE1
-
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study
NCT05104983 ·Status: RECRUITING ·Phase: PHASE2
-
A Phase II, Parallel Group, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Thalidomide in Reducing Weight Loss in Adults With HIV Wasting Syndrome
NCT00002127 ·Status: COMPLETED ·Phase: PHASE2
-
Decisional Capacity and Informed Consent in Fragile X Syndrome
NCT02465931 ·Status: COMPLETED ·Phase: NA